Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Bernstein Reaffirms Their Hold Rating on Novo Nordisk (0QIU)
Bernstein analyst Florent Cespedes maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK620.00.
Hosted on MSN7h
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...
Is Novo Nordisk A/S (NVO) the Best Global Stock to Buy According to Hedge Funds?
We recently published a list of 12 Best Global Stocks to Buy According to Hedge Funds. In this article, we are going to take ...
pharmaphorum22h
Novo Nordisk leaps on new obesity drug data
Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...
pharmaphorum22h
Novo Nordisk steps up sickle cell push with $1.1bn Forma buy
Novo Nordisk has doubled down on position in the sickle cell disease (SCD) category with a $1.1 billion agreement to acquire Forma Therapeutics, and its therapeutic candidate etavopivat ...